





Business Action to Stop Counterfeiting and Piracy (BASCAP) is a cross border initiative that connects all business sectors worldwide in the fight against counterfeiting and piracy.

Launched by the International Chamber of Commerce (ICC) it aims to support individual company and organizational efforts and amplify business messages with national governments and intergovernmental organizations in tackling the crime.

This global and united approach is vital in identifying and addressing intellectual property rights (IPR) issues more efficiently. It gives the industry a stronger voice when petitioning for greater commitments by local, national and international officials in the enforcement and protection of intellectual property rights.



BASCAP goals:

- Increase public and political awareness and understanding of counterfeiting and piracy activities and the associated economic and social harm
- Compel government action and the allocation of resources towards improved IPR enforcement
- Create a culture change where intellectual property is respected and protected

BASCAP CHINAG Working Group is established in 2018

- Secure support for BASCAP positions on China specific legislative and enforcement issues
- Leverage ICC China's relationship with its government "parent", CCPIT, to get Government awareness and action on BASCAP priority issues and recommendations.
- Leverage the membership of Alibaba and other Chinese platforms in ICC China to get further BASCAP's relationship with the platforms and gain support for BASCAP's positions on best practice recommendations.
- Seek to improve the protection afforded to intellectual property rights holders under the Chinese copyright law and Penal






Johnson GLOBAL BRAND PROTECTION


Proactive Online Monitoring on Pharm Online Sales in China

Alan Liu APAC Dir, Global Brand Protection

Transformation of Pharm E-commerce market in China







Hospital terminal (1087.7 billion) Retail terminal (310.0 billion) Network terminal (155.6 billion)	In-patient drugs (50%, 781.5 billion)	Out-patient RX (20%, 306.2 billion) Injection (10%, 156.3 billion) Non-injection (6%, 99.9 billion)	
		Out-patient OTC (3%, 50.0 billion)	
	RX (12%, 180.3 billion)	OTC (8%, 129.7 billion)	
	RX (4.9%, 76.6 billion)	OTC (5%, 79.0 billion)	




E-commerce will facilitate the reconstruction of traditional pharm value chain

Legend: New or changed link Pharmaceutical Pharmaceutical Logistics Medical institutions Patients distribution centers wholesalers enterprises: Service-oriented profit making Future value chain With the expansion Still controlling the Agency simplified of market, third factory prices, but Retail pharmacies High concentration party logistics to the pharmacy Increased rights Differentiated join the competition competition will of choice impacts on the be more market Improved position independent and -oriented, and the retail pharmacies cost performance is everything Pharmaceutical E-commerce To break through the traditional pharmaceutical circulation pattern Medical digital transformation and big data Integration of regulations

Pharm E-commerce pattern after transformation





Tough Call



Pharm online sales: OTC VS Rx

《药品流通管理办法》第二十一条和四十二条规定,药品生产、经营企业不得采用邮售、互联网交易等方式直接向公众销售处方药,违者将责令改正,给予警告,并处销售药品货值金额二倍以下的罚款,但是最高不超过三万元。

Rx Online is illegitimate in China now.

What's the real world?

- we have two **GREY MARKETS**



TOP 11 Online pharmacies in China

Categories	Platforms		
ウーナは告 (Third party)	八百方		
第三方挂靠 (Third-party affiliation)	快易捷		
aiillatioii)	药房网商城		
	好药师		
	健客网		
自营 (self-run)	康爱多		
	康德乐(原百济新特药)		
	仁和药房网		
白带(calf runa) , 每二十块告(Third	1药网		
自营(self run)+第三方挂靠(Third- party affiliation)	京东		
party anniation)	天猫		

PF				
ORDER(REGISTRATION IS REQUIERED)	PRESCRIPTION (IS REQUIRED)	PAYMENT	PLATFORM	
Υ	Y	PAY ON DELIVERY	天猫 京东	
Υ	Υ	PAY ON DELIVERY	1药网	
Υ	Y	PAY ON DELIVERY	康爱多 康德乐 健客网 八百方 仁和药房网 好药师	
N	N	ONLINE PAYMENT	药房网商城	
N	N	THIRD-PARTY GUAREENTE	快易捷	



Risk of Ecommerce Grey Market and Reasons

Paid for on delivery allowing online pharmacies to classify the transactions as "offline"

Rx freely available on ecommerce channel as sellers take advantage of loophole

The third party affiliation model is "apparently designed to circumvent the ban online sale of Rx.

Online pharmacies host the listings, take a marketing fee from the stores and deliver the orders through courier companies they part own.



Online Pharmacies

Rx Sale online – grey market

Drug Name	天猫	京东	1药网	八百方	药房网商 城	康爱多	康德乐	仁和药房 网	健客网	好药师	快易捷
01	N	N	N	N	Υ	N	Υ	N	N	N	Υ
02	Ν	N	N	Ν	N	N	Ν	Ν	N	N	Y
03	Ν	N	Ν	N	Υ	N	Υ	N	N	N	N
04	N	N	N	Ν	N	N	N	N	N	Ν	Y
O5	N	N	N	N	Υ	N	Υ	N	N	N	Y
R1	Y	N	Y	Y	Y	Y	Υ	N	Y	Y	Y
R2	Υ	Y	Υ	Υ	Υ	Y	Y	Y	Υ	Y	Y


Thresholds for Monitoring and TPs

Platform	Platform Category	Price	Inventory	Offline Entities	
High Risky?	Self-run or third party affiliation	Obviously Low	Big or Small?	Low Tier distributors? Bad Reputation?	





What We Know...




THE RISK FROM ECCOMERCE

...Vs. What We Don't Know

GREY MARKET IN NON-ECCOMERCE ONLINE CHANNEL

Online Monitoring & Screening Procedure and Coverage













65 keywords






















Platform

Illegitimate and Counterfeit Drugs – Postings




Estimation based on the Industrial URL searching

Category	WeChat Contact	QQ Contact	Phone Contact	URL	URL with Contact Information	HIT Ratio
Online talking group	21	19	25	2,829	1,198	42.35%
Online Q&A	8	2	5	1,350	559	41.41%
Healthcare Portal	3			237	61	25.74%
BBS	2	2	1	149	34	22.82%
Independent Website	1	4	15	1,282	131	10.22%
other		1	5	916	69	7.53%








Statistical analysis on the content within online talking groups

Online Rx Sale via online Talking groups



THREHOLD 1 - DURATION OF DELIVERY(within 3 days or more than 3 days)







THREHOLD 2 - SUSPECT SOURCES(from sales reps or recycling)









THREHOLD 3 - PAYMENT METHODS(through irrelevant commodities)






THREHOLD 3 - PAYMENT METHODS (via invisible Taobao



postings) ** 南至宋 央京王田 中和出河至





WHERE WE SHALL GO?

